ZENBEKEBI Trademark

Trademark Overview


On Thursday, November 13, 2025, a trademark application was filed for ZENBEKEBI with the United States Patent and Trademark Office. The USPTO has given the ZENBEKEBI trademark a serial number of 99495143. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Thursday, November 13, 2025. This trademark is owned by Celgene Corporation. The ZENBEKEBI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases, central nervous system diseases, metabolic disorders, stroke, cancer, inflammatory diseases, respiratory diseases, infectious diseases, auto-immune diseases, solid organ transplant rejection, autoinflammatory disease, blood disease, multiple sclerosis, ulcerative colitis, cystic fibrosis, arthritis, and musculoskeletal and skin disease; Antivirals; Antibodies for medical purposes; Biological preparations for the treatment of cancer;; Pharmaceutical preparations for the treatment and prevention of Anticoagulants;; Pharmaceutical preparations for the treatment and prevention of Stem cells for medical purposes;; Pharmaceutical preparations for the treatment and prevention of Radiopharmaceutical preparations for the treatment of cancer and solid tumors;; Pharmaceutical preparations for the treatment and prevention of Diagnostic radiopharmaceutical preparations;; Pharmaceutical preparations for...
zenbekebi

General Information


Serial Number99495143
Word MarkZENBEKEBI
Filing DateThursday, November 13, 2025
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateThursday, November 13, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Indication of Colors claimedColor is not claimed as a feature of the mark.
Description of MarkThe mark consists of a "fin" image centered above the term ZENBEKEBI.
Goods and ServicesPharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases, central nervous system diseases, metabolic disorders, stroke, cancer, inflammatory diseases, respiratory diseases, infectious diseases, auto-immune diseases, solid organ transplant rejection, autoinflammatory disease, blood disease, multiple sclerosis, ulcerative colitis, cystic fibrosis, arthritis, and musculoskeletal and skin disease; Antivirals; Antibodies for medical purposes; Biological preparations for the treatment of cancer;; Pharmaceutical preparations for the treatment and prevention of Anticoagulants;; Pharmaceutical preparations for the treatment and prevention of Stem cells for medical purposes;; Pharmaceutical preparations for the treatment and prevention of Radiopharmaceutical preparations for the treatment of cancer and solid tumors;; Pharmaceutical preparations for the treatment and prevention of Diagnostic radiopharmaceutical preparations;; Pharmaceutical preparations for the treatment and prevention of Diagnostic preparations for medical purposes.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, November 13, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCelgene Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543

Trademark Events


Event DateEvent Description
Thursday, November 13, 2025NEW APPLICATION ENTERED
Thursday, November 13, 2025APPLICATION FILING RECEIPT MAILED